ischaemia

R&D

pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.

News

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.